3
제2항에 있어서, (1S, 5R, 6S)-2-[(1R)-1-[(3R)-1-에틸피롤리딘-2-온-3-일]히드록시메틸]-6-[(1R)-1-히드록시에틸]-1-메틸-2-카르바페넴-3-카르복실산; (1S, 5R, 6S)-2-[(1R)-1-[(3S)-1-에틸피롤리딘-2-온-3-일]히드록시메틸]-6-[(1R)-1-히드록시에틸]-1-메틸-2-카르바페넴-3-카르복실산; (1S, 5R, 6S)-2-[(1R)-1-[(3R)-1-메틸피롤리딘-2-온-3-일]히드록시메틸]-6-[(1R)-1-히드록시에틸]-1-메틸-2-카르바페넴-3-카르복실산; (1S, 5R, 6S)-2-[(1R)-1-[(3S)-1-메틸피롤리딘-2-온-3-일]히드록시메틸]-6-[(1R)-1-히드록시에틸]-1-메틸-2-카르바페넴-3-카르복실산; (1S, 5R, 6S)-2-[(1R)-1-[(3R)-1-이소프로필피롤리딘-2-온-3-일]히드록시메틸]-6-[(1R)-1-히드록시에틸]-1-메틸-2-카르바페넴-3-카르복실산; (1S, 5R, 6S)-2-[(1R)-1-[(3S)-1-이소프로필피롤리딘-2-온-3-일]히드록시메틸]-6-[(1R)-1-히드록시에틸]-1-메틸-2-카르바페넴-3-카르복실산; (1S, 5R, 6S)-2-[(1R)-1-[(3R)-1-노르말부틸피롤리딘-2-온-3-일]히드록시메틸]-6-[(1R)-1-히드록시에틸]-1-메틸-2-카르바페넴-3-카르복실산; (1S, 5R, 6S)-2-[(1R)-1-[(3S)-1-노르말부틸피롤리딘-2-온-3-일]히드록시메틸]-6-[(1R)-1-히드록시에틸]-1-메틸-2-카르바페넴-3-카르복실산; (1S, 5R, 6S)-2-[(1R)-1-[(3R)-1-아제티딘-2-온-3-일]히드록시메틸]-6-[(1R)-1-히드록시에틸]-1-메틸-2-카르바페넴-3-카르복실산; (1S, 5R, 6S)-2-[(1R)-1-[(3S)-1-아제티딘-2-온-3-일]히드록시메틸]-6-[(1R)-1-히드록시에틸]-1-메틸-2-카르바페넴-3-카르복실산; (1S, 5R, 6S)-2-[(1R)-1-[(3R)-1-피롤리딘-2-온-3-일]히드록시메틸]-6-[(1R)-1-히드록시에틸]-1-메틸-2-카르바페넴-3-카르복실산; 및 (1S, 5R, 6S)-2-[(1R)-1-[(3S)-1-피롤리딘-2-온-3-일]히드록시메틸]-6-[(1R)-1-히드록시에틸]-1-메틸-2-카르바페넴-3-카르복실산으로 이루어지는 군으로부터 선택된 카르바페넴 유도체 화합물 및 그의 약제학상이나 수의학적으로 허용가능한 염
|